Preclinical SPECT/MR Molecular Imaging System Reduces Radiation Dose
By MedImaging International staff writers Posted on 26 Jun 2013 |
A new preclinical single photon emission tomography and magnetic resonance (SPECT/MR) hybrid molecular imaging system has exceptional molecular imaging capabilities in terms of potential preclinical and clinical applications, cost-effective technologic innovation, and reduction of patient exposure to ionizing radiation.
The technology was presented in June 2013 at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 annual meeting, held in Vancouver (BC, Canada). “We are pioneering simultaneous SPECT and MR imaging technologies now demonstrated in preliminary small animal studies,” said Benjamin M.W. Tsui, PhD, director of the division of medical imaging physics in the department of radiology, and a professor of radiology, electrical and computer, biomedical engineering, and environmental health sciences at Johns Hopkins University (Baltimore, MD, USA). “We have been building the technology with our industrial partner, TriFoil Imaging [Northridge, CA, USA]—formerly the preclinical business of Gamma Medica, Inc.—for the past five years and have sufficient data now to show that it works. This presents a unique multimodality system that images mice down to a spatial resolution of less than1 mm at high detection efficiency.”
SPECT/MR represents a completely different imaging modality from other hybrid systems such as positron emission tomography/ computed tomography (PET/CT) and simultaneous PET/magnetic resonance imaging (PET/MRI) by allowing hybrid imaging with biomarkers labeled with a wide range of radionuclides. SPECT/MRI has a range of possible applications, including but not limited to imaging for cardiovascular and neurologic diseases, cancer, thyroid and other endocrine disorders, trauma, inflammation, and infection.
To generate a SPECT insert that performs in the magnetic field of an MRI system, the developers incorporated 16 x 16 pixel and 1.6-mm pixel pitch cadmium zinc telluride (CZT) solid-state detectors that directly convert incoming photons into electrical signals that are not disturbed by the static magnetic field. The SPECT insert also houses a state-of-the-art “multi-pinhole” collimator that provides both high spatial resolution and capacity for the detection of photons from small animals injected with available or new nuclear medicine biomarkers that use radionuclides to illustrate physiologic functions of the body. Unlike PET imaging, SPECT has the added benefit of being able to identify photons of different energies from multiple radionuclide-labeled biomarkers for fully customized and application-specific multifunctional imaging.
The SPECT/MR system’s key features include the elimination of the radiation dose associated with CT and the much lower cost of building the technology compared to PET/MR, which cost approximately USD 5.5 million for a clinical system. Dr. Tsui noted, however, that the technology is meant not to replace other technologies but instead to further diversify alternatives for biomedical investigators and clinicians to optimize research and patient care. SPECT/MR could roll out into human trials in the not-too-distant future. “We are confident that with sufficient funding we can build a SPECT/MR system for human brain studies in about two years and begin clinical studies by the third year,” Dr. Tsui estimated.
Related Links:
Johns Hopkins University
TriFoil Imaging
The technology was presented in June 2013 at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2013 annual meeting, held in Vancouver (BC, Canada). “We are pioneering simultaneous SPECT and MR imaging technologies now demonstrated in preliminary small animal studies,” said Benjamin M.W. Tsui, PhD, director of the division of medical imaging physics in the department of radiology, and a professor of radiology, electrical and computer, biomedical engineering, and environmental health sciences at Johns Hopkins University (Baltimore, MD, USA). “We have been building the technology with our industrial partner, TriFoil Imaging [Northridge, CA, USA]—formerly the preclinical business of Gamma Medica, Inc.—for the past five years and have sufficient data now to show that it works. This presents a unique multimodality system that images mice down to a spatial resolution of less than1 mm at high detection efficiency.”
SPECT/MR represents a completely different imaging modality from other hybrid systems such as positron emission tomography/ computed tomography (PET/CT) and simultaneous PET/magnetic resonance imaging (PET/MRI) by allowing hybrid imaging with biomarkers labeled with a wide range of radionuclides. SPECT/MRI has a range of possible applications, including but not limited to imaging for cardiovascular and neurologic diseases, cancer, thyroid and other endocrine disorders, trauma, inflammation, and infection.
To generate a SPECT insert that performs in the magnetic field of an MRI system, the developers incorporated 16 x 16 pixel and 1.6-mm pixel pitch cadmium zinc telluride (CZT) solid-state detectors that directly convert incoming photons into electrical signals that are not disturbed by the static magnetic field. The SPECT insert also houses a state-of-the-art “multi-pinhole” collimator that provides both high spatial resolution and capacity for the detection of photons from small animals injected with available or new nuclear medicine biomarkers that use radionuclides to illustrate physiologic functions of the body. Unlike PET imaging, SPECT has the added benefit of being able to identify photons of different energies from multiple radionuclide-labeled biomarkers for fully customized and application-specific multifunctional imaging.
The SPECT/MR system’s key features include the elimination of the radiation dose associated with CT and the much lower cost of building the technology compared to PET/MR, which cost approximately USD 5.5 million for a clinical system. Dr. Tsui noted, however, that the technology is meant not to replace other technologies but instead to further diversify alternatives for biomedical investigators and clinicians to optimize research and patient care. SPECT/MR could roll out into human trials in the not-too-distant future. “We are confident that with sufficient funding we can build a SPECT/MR system for human brain studies in about two years and begin clinical studies by the third year,” Dr. Tsui estimated.
Related Links:
Johns Hopkins University
TriFoil Imaging
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure